MNPR Projected Dividend Yield
Monopar Therapeutics Inc ( NASDAQ : MNPR )Monopar Therapeutics is a biopharmaceutical company focused on developing proprietary therapeutics for cancer patients. Co.'s compounds in development: Validive®, a Phase 2b/3 clinical stage, mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a Phase 1b clinical stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; MNPR-101, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for cancers and COVID-19; and an early stage camsirubicin analog, MNPR-202, for various cancers. 20 YEAR PERFORMANCE RESULTS |
MNPR Dividend History Detail MNPR Dividend News MNPR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |